Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model

Differential expression of microRNAs (miRNAs) has been demonstrated in various cancers, including pancreatic cancer (PC). Due to the lack of tissue samples from early-stages of PC, the stage-specific alteration of miRNAs during PC initiation and progression is largely unknown. In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model. At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls. Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice. In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice. Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in downregulation of KRAS and MSST1 expression. Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.

[1]  Xiaodong Chen,et al.  MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2. , 2014, Oncology reports.

[2]  S. Batra,et al.  MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. , 2014, Current pharmaceutical design.

[3]  Suyun Huang,et al.  Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. , 2014, Gastroenterology.

[4]  B. Hou,et al.  [Expression of miR-216a in pancreatic cancer and its clinical significance]. , 2012, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[5]  S. Batra,et al.  Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy , 2012, Journal of Hematology & Oncology.

[6]  Ji-Lin Wang,et al.  MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. , 2011, Carcinogenesis.

[7]  J. Marshall,et al.  Tissue and Serum microRNAs in the KrasG12D Transgenic Animal Model and in Patients with Pancreatic Cancer , 2011, PloS one.

[8]  Jong Y. Park,et al.  MicroRNAs in pancreatic ductal adenocarcinoma. , 2011, World journal of gastroenterology.

[9]  Xian-gui Hu,et al.  MicroRNA 483‐3p suppresses the expression of DPC4/Smad4 in pancreatic cancer , 2011, FEBS letters.

[10]  Zhaohui Lu,et al.  The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. , 2010, Carcinogenesis.

[11]  C. Croce,et al.  Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.

[12]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[13]  E. Steingrímsson,et al.  miR-148 Regulates Mitf in Melanoma Cells , 2010, PloS one.

[14]  Ugo Boggi,et al.  MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. , 2010, Cancer research.

[15]  S. Batra,et al.  MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. , 2010, Cancer letters.

[16]  Yong-Tae Kim,et al.  Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer , 2010, PloS one.

[17]  L. Buscail,et al.  MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. , 2010, Clinical chemistry.

[18]  M. Gaestel,et al.  p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication , 2010, Proceedings of the National Academy of Sciences.

[19]  G. Calin,et al.  MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. , 2010, Endocrine-related cancer.

[20]  Sun-Mi Park,et al.  The role of let-7 in cell differentiation and cancer. , 2010, Endocrine-related cancer.

[21]  D. Katsaros,et al.  Down-regulation of dicer expression in ovarian cancer tissues. , 2010, Clinical biochemistry.

[22]  O. Kent,et al.  A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells , 2009, Cancer biology & therapy.

[23]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[24]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[25]  L. Buscail,et al.  let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. , 2009, Human gene therapy.

[26]  K. Ohuchida,et al.  MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance , 2009, Molecular Cancer Therapeutics.

[27]  J. Chi,et al.  Aberrant expression of microRNA biosynthetic pathway components is a common feature of haematological malignancy , 2009, British journal of haematology.

[28]  Qizhi Yao,et al.  Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real-Time PCR Analysis , 2009, World Journal of Surgery.

[29]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[30]  M. Korc,et al.  Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. , 2008, Clinical chemistry.

[31]  Wendy Frankel,et al.  MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival , 2008, Journal of Gastrointestinal Surgery.

[32]  T. Brabletz,et al.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells , 2008, EMBO reports.

[33]  Reuven Agami,et al.  miR-148 targets human DNMT3b protein coding region. , 2008, RNA.

[34]  Rudolf Jaenisch,et al.  Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17∼92 Family of miRNA Clusters , 2008, Cell.

[35]  Shuomin Zhu,et al.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis , 2008, Cell Research.

[36]  Yuriy Gusev,et al.  Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. , 2007, RNA.

[37]  E. Kistner,et al.  Let-7 expression defines two differentiation stages of cancer , 2007, Proceedings of the National Academy of Sciences.

[38]  T. Davison,et al.  MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma , 2007, Oncogene.

[39]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[40]  Anindya Dutta,et al.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. , 2007, Genes & development.

[41]  C. Mayr,et al.  Disrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation , 2007, Science.

[42]  M. Korc,et al.  The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia , 2007, Proceedings of the National Academy of Sciences.

[43]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[44]  Stefano Volinia,et al.  MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Eugene Berezikov,et al.  Approaches to microRNA discovery , 2006, Nature Genetics.

[46]  Prasenjit Dey,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[47]  Ralph Weissleder,et al.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[48]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[49]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[50]  V. Kim.  MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.

[51]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[52]  K. Lindblad-Toh,et al.  Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals , 2005, Nature.

[53]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[54]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[55]  K. Czaplinski,et al.  Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. , 2004, RNA.

[56]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[57]  B. Cullen,et al.  Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. , 2003, Genes & development.

[58]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[59]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[60]  Emily Bernstein,et al.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells , 2000, Nature.

[61]  B. Reinhart,et al.  The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans , 2000, Nature.

[62]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[63]  H. Horvitz,et al.  Heterochronic mutants of the nematode Caenorhabditis elegans. , 1984, Science.

[64]  S. Batra,et al.  Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. , 2015, Advanced drug delivery reviews.

[65]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[66]  S. Batra,et al.  Current status of molecular markers for early detection of sporadic pancreatic cancer. , 2011, Biochimica et biophysica acta.

[67]  Lu Wang,et al.  MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. , 2011, Cancer research.

[68]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[69]  Norbert Senninger,et al.  EP300—A miRNA‐regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas , 2010, International journal of cancer.

[70]  Dileep N. Lobo,et al.  Knockdown of microRNA-21 Inhibits Proliferation and Increases Cell Death by Targeting Programmed Cell Death 4 (PDCD4) in Pancreatic Ductal Adenocarcinoma , 2010, Journal of Gastrointestinal Surgery.

[71]  T. Rana,et al.  Illuminating the silence: understanding the structure and function of small RNAs , 2007, Nature Reviews Molecular Cell Biology.

[72]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[73]  Chih-Hao Chang,et al.  Molecular and Cellular Pathobiology Microrna Signature and Expression of Dicer and Drosha Can Predict Prognosis and Delineate Risk Groups in Neuroblastoma , 2022 .